Measuring of Alpha-1 Antitrypsin Concentration by Nephelometry or Turbidimetry.
Alpha-1 antitrypsin deficiency
Immunoassays
Laboratory diagnosis
Nephelometry
Turbidimetry
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2024
2024
Historique:
medline:
18
12
2023
pubmed:
18
12
2023
entrez:
18
12
2023
Statut:
ppublish
Résumé
Most clinical laboratories quantify alpha-1 antitrypsin using either nephelometry or turbidimetry techniques because they are commercially available, amenable to automation, and precise. Both methods are based on light scatter. The foundation of both techniques is based on incubation of the specimen with anti-AAT polyclonal antibody solution, a polymer matrix between endogenous AAT and the reagent antibodies forms, leading to production of light-scattering large particles. Although these two terms are sometimes used synonymously, technically speaking they are not.Nephelometry measures the amount of turbidity or cloudiness of a solution by directly quantifying the intensity of the light scattered by insoluble particles in the sample. Therefore, this technique measures the light that passes through the sample, with the detector being placed at an angle from the sample. Turbidimetry is the process of measuring the loss of intensity of the light transmitted linearly through a sample caused by the scattering effect of insoluble particles. The decrease in light transmission is measured compared to a reference, and the absorbed light is quantified.Beyond specific technical differences between both techniques, there are two major differences between the two procedures that may influence the results. First, the concentration of the sample and the resulting intensity of scattered light relative to the intensity of the light source is one major factor. Second, the size of the scattering particles is also a key differentiating factor. This chapter describes the technical requirements, the different protocols, and the clinical applicability of these two techniques in the diagnosis of alpha-1 antitrypsin deficiency.
Identifiants
pubmed: 38108973
doi: 10.1007/978-1-0716-3605-3_12
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
123-133Informations de copyright
© 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Stoller JK, Aboussouan LS (2005) Alpha1-antitrypsin deficiency. Lancet 365:2225–2236
doi: 10.1016/S0140-6736(05)66781-5
pubmed: 15978931
Stoller JK, Sandhaus RA, Turino G et al (2005) Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem. Chest 128:1989–1994
doi: 10.1378/chest.128.4.1989
pubmed: 16236846
Laurell CB, Eriksson S (2009) The electrophoretic α;1-globulin pattern of serum in α;1-antitrypsin deficiency. Scand J Clin Lab Invest 15:132–140
doi: 10.1080/00365516309051324
Laurell CB, Eriksson S (1965) The serum alpha-L-antitrypsin in families with hypo-alpha-L-Antitrypsinemia. Clin Chim Acta 11:395–398
doi: 10.1016/0009-8981(65)90184-1
pubmed: 14347984
Eriksson S (1964) Pulmonary emphysema and alpha1-antitrypsin deficiency. Acta Med Scand 175:197–205
doi: 10.1111/j.0954-6820.1964.tb00567.x
pubmed: 14124635
Franciosi AN, Alkhunaizi MA, Woodsmith A et al (2021) Alpha-1 antitrypsin deficiency and tobacco smoking: exploring risk factors and smoking cessation in a registry population. COPD 18:76–82
doi: 10.1080/15412555.2020.1864725
pubmed: 33557645
Seixas S, Marques PI (2021) Known mutations at the cause of alpha-1 antitrypsin deficiency an updated overview of SERPINA1 variation spectrum. Appl Clin Genet 14:173–194
doi: 10.2147/TACG.S257511
pubmed: 33790624
pmcid: 7997584
(2023) Global initiative for obstructive lung disease. 2023 report in [ https://goldcopd.org/ ]
Miravitlles M, Calle M, Molina J et al (2022) Spanish COPD guidelines (GesEPOC) 2021: updated pharmacological treatment of stable COPD. Archivos de bronconeumologia 58:69–81
doi: 10.1016/j.arbres.2021.03.005
pubmed: 33840553
Martinez-Garcia MA, Maiz L, Olveira C et al (2018) Spanish guidelines on the evaluation and diagnosis of bronchiectasis in adults. Arch Bronconeumol (Engl Ed) 54:79–87
doi: 10.1016/j.arbr.2017.07.013
pubmed: 29128130
Kohnlein T, Janciauskiene S, Welte T (2010) Diagnostic delay and clinical modifiers in alpha-1 antitrypsin deficiency. Ther Adv Respir Dis 4:279–287
doi: 10.1177/1753465810376407
pubmed: 20660539
(1997) Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ 75:397–415
Miravitlles M, Dirksen A, Ferrarotti I et al (2017) European Respiratory Society statement: diagnosis and treatment of pulmonary disease in alpha1-antitrypsin deficiency. Eur Respir J 50:1700610
doi: 10.1183/13993003.00610-2017
pubmed: 29191952
Aboussouan LS, Stoller JK (2009) Detection of alpha-1 antitrypsin deficiency: a review. Respir Med 103:335–341
doi: 10.1016/j.rmed.2008.10.006
pubmed: 19013782
Lopez-Campos JL, Carrasco Hernandez L, Caballero Eraso C (2020) Implications of a change of paradigm in alpha1 antitrypsin deficiency augmentation therapy: from biochemical to clinical efficacy. J Clin Med 9:2526
doi: 10.3390/jcm9082526
pubmed: 32764414
pmcid: 7465600
Ruiz-Duque B, Banuls L, Reinoso-Arija R et al (2021) Methodologies for the determination of blood alpha1 antitrypsin levels: a systematic review. J Clin Med 10:5132
doi: 10.3390/jcm10215132
pubmed: 34768650
pmcid: 8584727
Brantly ML, Wittes JT, Vogelmeier CF et al (1991) Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes. Chest 100:703–708
doi: 10.1378/chest.100.3.703
pubmed: 1889260
Donato LJ, Snyder MR, Greene DN (2017) Measuring and interpreting serum AAT concentration. Methods Mol Biol 1639:21–32
doi: 10.1007/978-1-4939-7163-3_3
pubmed: 28752443
Sakornsakolpat P, Prokopenko D, Lamontagne M et al (2019) Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. Nat Genet 51:494–505
doi: 10.1038/s41588-018-0342-2
pubmed: 30804561
pmcid: 6546635
Ferrarotti I, Poplawska-Wisniewska B, Trevisan MT et al (2015) How can we improve the detection of alpha1-antitrypsin deficiency? PLoS One 10:e0135316
doi: 10.1371/journal.pone.0135316
pubmed: 26270547
pmcid: 4536179
Costa X, Jardi R, Rodriguez F et al (2000) Simple method for alpha1-antitrypsin deficiency screening by use of dried blood spot specimens. Eur Respir J 15:1111–1115
doi: 10.1034/j.1399-3003.2000.01521.x
pubmed: 10885432
Ferrarotti I, Scabini R, Campo I et al (2007) Laboratory diagnosis of alpha1-antitrypsin deficiency. Transl Res 150:267–274
doi: 10.1016/j.trsl.2007.08.001
pubmed: 17964515
Castells Martinez EM, Gonzalez EC, Tejeda, et al. (2018) An enzyme immunoassay for determining immunoreactive trypsinogen (IRT) in dried blood spots on filter paper using an ultra-microanalytical system. Appl Biochem Biotechnol 186:1034–1046
doi: 10.1007/s12010-018-2785-4
pubmed: 29808455
Gorrini M, Ferrarotti I, Lupi A et al (2006) Validation of a rapid, simple method to measure alpha1-antitrypsin in human dried blood spots. Clin Chem 52:899–901
doi: 10.1373/clinchem.2005.062059
pubmed: 16638961
Zillmer LR, Russo R, Manzano BM et al (2013) Validation and development of an immunonephelometric assay for the determination of alpha-1 antitrypsin levels in dried blood spots from patients with COPD. J Bras Pneumol 39:547–554
doi: 10.1590/S1806-37132013000500004
pubmed: 24310627
pmcid: 4075886
Miravitlles M, Dirksen A, Ferrarotti I et al (2017) European Respiratory Society statement: diagnosis and treatment of pulmonary disease in alpha(1)-antitrypsin deficiency. Eur Respir J 50:1700610
doi: 10.1183/13993003.00610-2017
pubmed: 29191952
Viedma JA, de la Iglesia A, Parera M et al (1986) A new automated turbidimetric immunoassay for quantifying alpha 1-antitrypsin in serum. Clin Chem 32:1020–1022
doi: 10.1093/clinchem/32.6.1020
pubmed: 3085977
Walsh RL, Dillon TJ, McLennan G (1992) A rapid procedure for the measurement of elastase inhibitory function of plasma and bronchoalveolar lavage fluid. Clin Biochem 25:263–270
doi: 10.1016/0009-9120(92)80031-B
pubmed: 1525982
Jonigk D, Al-Omari M, Maegel L et al (2013) Anti-inflammatory and immunomodulatory properties of alpha1-antitrypsin without inhibition of elastase. Proc Natl Acad Sci U S A 110:15007–15012
doi: 10.1073/pnas.1309648110
pubmed: 23975926
pmcid: 3773761
Lisowska-Myjak B, Sygitowicz G, Wolf B, Pachecka J (2001) Serum alpha-1-antitrypsin concentration during normal and diabetic pregnancy. Eur J Obstet Gynecol Reprod Biol 99:53–56
doi: 10.1016/S0301-2115(01)00356-6
pubmed: 11604186
Engler R (1995) [Acute-phase proteins in inflammation]. C R Seances Soc Biol Fil 189:563–578
Balduyck M, Odou MF, Zerimech F et al (2014) Diagnosis of alpha-1 antitrypsin deficiency: modalities, indications and diagnosis strategy. Rev Mal Respir 31:729–745
doi: 10.1016/j.rmr.2014.06.001
pubmed: 25391508
Sanders CL, Ponte A, Kueppers F (2018) The effects of inflammation on alpha 1 antitrypsin levels in a National Screening Cohort. COPD 15:10–16
doi: 10.1080/15412555.2017.1401600
pubmed: 29381093
Lopes AP, Mineiro MA, Costa F et al (2018) Portuguese consensus document for the management of alpha-1-antitrypsin deficiency. Pulmonology 24(Suppl 1):1–21
doi: 10.1016/j.pulmoe.2018.09.004
pubmed: 30473034